Clinical Trials Logo

Clinical Trial Summary

This is a multicenter, Phase I/II study in patients with non-resectable hepatocellular carcinoma following TACE treatment. Phase I (Open-label dose escalation) This study will be an open-label study with an Accelerated Phase and a Standard Phase. For the Accelerated Phase of the study, one patient per dose level (1 mg/kg, and 2 mg/kg) is planned. For the dose levels in the standard phase (4 mg/kg, 8 mg/kg and 16 mg/kg), it will follow the Fibonacci's rule of 3 + 3 design. All eligible patients who have received TACE treatment and recovered well, will be administrated PTX-9908 Injection intravenously one dose per day for 5 days on Week 1 (excludes weekends and public holidays), and one dose per week (on Day 8, Day 15, and Day 22) for 3 consecutive weeks. The 4-week treatment period, will be followed by a 2-week follow-up period. Phase II (Randomized placebo controlled dose expansion) The objective of phase II is to further evaluate the safety, tolerability and antitumor activity of PTX-9908 Injection for patients with non-resectable hepatocellular carcinoma following TACE treatment. Approximately 24 eligible patients who have received TACE treatment and recovered, will be randomized to PTX-9908 Injection using the predetermined dose in phase I or the vehicle placebo in a 2:1 ratio. PTX-9908 Injection or placebo will be administered intravenously one dose per day for 5 days in Week 1 (excludes weekends and public holidays), and one dose per week till Week 12 (Day 78). The 12-week treatment period, will be followed by a 2-week follow-up period.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03812874
Study type Interventional
Source TCM Biotech International Corp.
Contact Chien-Hung Chen, MD, PhD
Phone +886 2312 3456
Email chenhcc@ntuh.gov.tw
Status Recruiting
Phase Phase 1/Phase 2
Start date October 6, 2020
Completion date December 30, 2024

See also
  Status Clinical Trial Phase
Completed NCT03289533 - A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100) Phase 1
Terminated NCT01141478 - Proton Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With HCC Exceeding San Francisco Criteria N/A
Recruiting NCT05580835 - PET / MR With PSMA for Diagnosis and Staging of Hepatocellular Carcinoma N/A
Active, not recruiting NCT05389527 - Pembrolizumab and Lenvatinib for Resectable Hepatocellular Carcinoma Phase 2
Not yet recruiting NCT04560751 - TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (Prolong)
Withdrawn NCT02939807 - A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular Carcinoma Phase 2
Completed NCT01915602 - Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC) Phase 2
Completed NCT04970212 - Safety and Effectiveness of BioTraceIO Lite for Tissue Damage Assessment Following Liver Tissue Ablation Procedures
Recruiting NCT02403544 - Phase I Study of Image-Guided Radiation Concurrent With Double-Agent Chemotherapy for Hepatocellular Carcinoma Phase 1
Completed NCT01897038 - A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular Carcinoma Phase 1
Terminated NCT01337492 - Pilot Study Sorafenib as Bridge to Orthotopic Liver Transplantation (OLT) Phase 0
Terminated NCT01020812 - Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma Phase 1/Phase 2
Completed NCT01012011 - Regulatory Post Marketing Surveillance Study on Nexavar® N/A
Completed NCT01003015 - Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma Phase 2
Completed NCT00559455 - Phase II Study of Eloxatin+5-FU/LV in Patients With Unresectable Hepatocellular Carcinoma Phase 2
Recruiting NCT00384800 - A Phase II Study of Tegafur/Uracil (UFUR®)Plus Thalidomide for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma (HCC) Phase 2
Terminated NCT00582400 - A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver Phase 2
Completed NCT00056992 - Testing of ADI-PEG in Hepatocellular Carcinoma Phase 2
Completed NCT02859324 - A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC) Phase 1/Phase 2
Terminated NCT02439008 - Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response N/A